Alexander Drilon, MD | Authors

Articles

Analyzing the Data for Entrectinib in ROS1 TKI-Naive Patients With NSCLC

June 06, 2019

Alexander Drilon, MD, clinical director, Early Drug Development Service, and associate professor of the Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, discusses the data examining the role of entrectinib in patients with non–small cell lung cancer who are naïve to treatment with a ROS1 tyrosine kinase inhibitor.

The Importance of CNS Activity in Agents for NSCLC

October 20, 2017

Alexander Drilon, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the importance of central nervous system (CNS) activity in agents for the treatment of non–small cell lung cancer (NSCLC).